Humacyte, Inc. 2025-2026 Proxy Voting Records

Description as filed by funds: Election of three Class II directors to serve until the 2029 annual meeting of stockholders: John P. Bamforth

Humacyte, Inc.’s own tally for this item (“Elect Director: John P. Bamforth”): 48,332,651 for, 13,968,428 withheld, per its Form 8-K filed June 9, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1 – Election of Directors The stockholders elected each of the three Class II directors who were nominated to serve until the Company's 2029 annual meeting of stockholders or until such director's successor is elected, or until such director's earlier death, resignation or removal.”
Support: 78% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 34 asset managers below reported 4,460 for, 1,250,295 withheld, 928,384 abstained.

Showing the 25 largest of 34 asset managers. See all 34 in the interactive database.

Description as filed by funds: Election of three Class II directors to serve until the 2029 annual meeting of stockholders: Kathleen Sebelius

Humacyte, Inc.’s own tally for this item (“Elect Director: Kathleen Sebelius”): 52,765,738 for, 9,535,341 withheld, per its Form 8-K filed June 9, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1 – Election of Directors The stockholders elected each of the three Class II directors who were nominated to serve until the Company's 2029 annual meeting of stockholders or until such director's successor is elected, or until such director's earlier death, resignation or removal.”
Support: 85% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 34 asset managers below reported 1,985,859 for, 195,385 withheld, 1,895 abstained.

Showing the 25 largest of 34 asset managers. See all 34 in the interactive database.

Description as filed by funds: Election of three Class II directors to serve until the 2029 annual meeting of stockholders: Keith Anthony Jones

Humacyte, Inc.’s own tally for this item (“Elect Director: Keith Anthony Jones”): 52,871,152 for, 9,429,927 withheld, per its Form 8-K filed June 9, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1 – Election of Directors The stockholders elected each of the three Class II directors who were nominated to serve until the Company's 2029 annual meeting of stockholders or until such director's successor is elected, or until such director's earlier death, resignation or removal.”
Support: 85% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 34 asset managers below reported 2,025,861 for, 155,383 withheld, 1,895 abstained.

Showing the 25 largest of 34 asset managers. See all 34 in the interactive database.

Description as filed by funds: APPROVAL OF AN AMENDMENT TO HUMACYTE, INC.'S SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION, AS AMENDED, TO INCREASE THE TOTAL NUMBER OF AUTHORIZED SHARES OF COMMON STOCK FROM 350,000,000 SHARES TO 550,000,000 SHARES.

Humacyte, Inc.’s own tally for this item (“5. Approval of an Amendment to the Certificate of Incorporation to Increase the Number of Authorized Shares of Common Stock”): 102,313,282 for, 23,088,322 against — passed, per its Form 8-K filed June 9, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The stockholders approved the Amendment to increase the number of authorized shares of common stock from 350,000,000 shares to 550,000,000 shares.”
Support: 82% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 34 asset managers below reported 2,183,130 for, 8 against, 1 abstained.

Showing the 25 largest of 34 asset managers. See all 34 in the interactive database.

Description as filed by funds: Approval, on an advisory basis, of the compensation paid to Humacyte, Inc.'s named executive officers.

Humacyte, Inc.’s own tally for this item (“2. Approval of Named Executive Officer Compensation”): 40,100,324 for, 19,493,367 against — passed, per its Form 8-K filed June 9, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal No. 2 – Approval of Named Executive Officer Compensation The stockholders approved, on an advisory basis, the compensation paid to the Company's named executive officers, as described in the executive compensation section of the proxy statement.”
Support: 67% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 34 managers: 1,866,740 for, 316,396 against, 3 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 106 managers: 3,792,479 for, 7,582,416 against, 28,263 1 year. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: Approval, on an advisory basis, of the frequency of future advisory votes to approve the compensation paid to Humacyte, Inc.'s named executive officers.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports, all 34 managers: 1 for, 1 abstained, 2,183,105 1 year, 31 unknown. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 101 managers: 28,263 against, 5,323,003 1 year, 1,523 2 year, 900 3 year. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: Ratification of the selection of PricewaterhouseCoopers LLP by the Board of Directors as Humacyte, Inc.'s independent registered public accounting firm for the year ending December 31, 2026.

Humacyte, Inc.’s own tally for this item (“4. Ratification of the Selection of Independent Registered Public Accounting Firm The appointment of Pricewaterhouse Coopers LLP as the Company's independent registered public accounting firm for the fiscal year ending D”): 125,187,135 for, 1,654,285 against — passed, per its Form 8-K filed June 9, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 4 – Ratification of the Selection of Independent Registered Public Accounting Firm The appointment of Pricewaterhouse Coopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified.”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 34 asset managers below reported 2,183,138 for.

Showing the 25 largest of 34 asset managers. See all 34 in the interactive database.